Carcinoma, Pancreatic Ductal clinical trials

Who develops what

Every programme with a company-led study here in the last two years, whatever its size: 4 programmes from 3 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programmes are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

3 more in limited or earlier use — sign in to see them, free.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

• 15 Dec 2026 est.Acoustic Cluster Therapy · EXACT Therapeutics AS · Phase 2 registry mapping onlyNCT06850623 Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer — primary endpoint: ORR (Overall response rate), defined as the number of participants with measurable disease at baseline who have a confirmed Complete Response or confirmed Partial Response according to RECIST Version 1.1. · 25 enrolled
• Sep 2027 est.relacorilant · Corcept Therapeutics · Phase 2 main aimNCT07259317 Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma — primary endpoint: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1) · 80 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. Phase 4 trial recorded: a phase 4 study exists somewhere; approval here is not checked. Not read yet: approvals and labels, exclusivity, licences, line of therapy, academic comparators, sales.